Navigate to Other Instruments
Avidity Biosciences, Inc.
RNAMKey Takeaways
Last updated: 2026-04-13- •Replimune (REPLI) closed at $4.76 on April 10, 2026 — a ~20% single-day drop and 51% YTD decline following a second FDA Complete Response Letter for RP1.
- •Leverage risk is extreme: a 50x long CFD opened at $5.91 would have been liquidated intraday, as the 20% decline represents ~10x the initial margin at that leverage level.
- •A February 2026 SEC filing warned a second rejection could make RP1 development 'no longer viable,' with Phase 3 completion not expected until January 2029.
- •Cross-market contagion targets biotech ETFs (XBI, IBB) as the FDA rejection reinforces sector-wide regulatory uncertainty flagged by nearly half of RBC Capital Markets-surveyed investors.
- •FDA leadership transition (Vinay Prasad departing by end of April 2026) adds short-term regulatory uncertainty across clinical-stage oncology names.
Price & Market Structure
Trading Regime Status
Glossary
Key listed-stock and CFD terms, one line each — so the page is unambiguous for both readers and AI answer engines.
| Stock CFD | A contract for difference on a share price — price exposure only, not ownership of the underlying shares. |
|---|---|
| Extended hours | Pre-market and after-hours trading outside the exchange’s regular session. |
| Basis risk | The risk that the CFD reference price and the exchange execution price do not move in step. |
| P/E | Price-to-earnings ratio = share price ÷ earnings per share; a common valuation gauge. |
| Gross margin | Gross profit ÷ revenue; reflects product-level profitability. |
| EPS | Earnings per share = net income ÷ diluted shares outstanding. |
Latest Pulses
Replimune Plunges 56% YTD After Second FDA Rejection: Leverage Risks and Biotech Sector Contagion
As reported by FierceBiotech and BioPharma Dive, the U.S. Food and Drug Administration issued a second Complete Response Letter (CRL) on April 10, 2026, rejecting Replimune Group's (NASDAQ: REPLI) RP1
Replimune's Second FDA Rejection: Layoffs Signal Binary-Risk Collapse for Biotech CFD Traders
On April 10, 2026, the U.S. Food and Drug Administration issued a second Complete Response Letter (CRL) rejecting Replimune Group, Inc.'s (NASDAQ: REPL) resubmitted Biologics License Application for R
Replimune's RP1 Faces Second FDA Verdict: What April 10 Means for Biotech CFD Traders
Replimune Group Inc. (NASDAQ: REPL) received a Complete Response Letter (CRL) from the FDA on July 22, 2025, rejecting its Biologics License Application for RP1 — an oncolytic herpes simplex virus — i
Get Started with Avidity Biosciences, Inc.
Start trading Avidity Biosciences, Inc. on CoinUnited.io with industry-leading leverage and zero fees.
Trade with Leverage
Trade RNAM CFDs with up to 1000x leverage on CoinUnited.io.
- Up to 1000x leverage
- Zero trading fees
- Advanced risk management tools
Explore Stocks
Browse the full stocks market on CoinUnited.io with 125+ instruments.
- 125+ stocks instruments
- Real-time market data
- Professional charting tools
Learn Stocks Trading
Read our in-depth research and analysis on stocks markets.
- Expert market analysis
- Technical analysis basics
- Daily market insights
How to Trade Avidity Biosciences, Inc.: Step-by-Step Guide
Learn how to trade Avidity Biosciences, Inc. (RNAM) on CoinUnited.io with up to 1000x leverageand zero trading fees. Follow this simple step-by-step guide to start CFD trading today.
Create Your CoinUnited.io Account
Sign up at CoinUnited.io in under a minute. You'll need an email address to get started.
- ✓Quick and free registration
- ✓Email and password setup
- ✓Two-factor authentication for security
Verify Your Identity
Complete the KYC verification process to unlock full trading features and higher limits.
- ✓Upload government-issued ID
- ✓Proof of address document
- ✓Usually verified within minutes
Deposit Funds
Fund your account using one of the supported deposit methods.
Deposit Methods
- •Cryptocurrency deposits (BTC, ETH, USDT)
- •Bank transfer available
- •No minimum deposit requirement
Find RNAM in the Stocks Section
Navigate to the stocks market section and search for RNAM. You can trade Avidity Biosciences, Inc. as a CFD with up to 1000x leverage.
- ✓Search for "RNAM" in the trading platform
- ✓Select CFD trading mode
- ✓Review the current price and market data
Place Your Trade
Choose your position direction (long or short), set your leverage, and enter your position size to trade Avidity Biosciences, Inc..
- ✓Long (buy) if you expect RNAM to rise
- ✓Short (sell) if you expect RNAM to fall
- ✓Set stop-loss and take-profit levels
Monitor & Manage Risk
Keep track of your open positions and manage risk with stop-loss orders and position sizing.
- ✓Monitor P&L in real-time
- ✓Adjust stop-loss as needed
- ✓Never risk more than you can afford to lose
Order Types
Market Order
Execute immediately at the current market price. Best for quick entries.
Limit Order
Set a specific price to enter. The order fills only when the market reaches your price.
Stop-Loss Order
Automatically close your position at a specified price to limit potential losses.
Important Tips
- • Start with a small position to understand how leverage works
- • Always set a stop-loss to protect your capital
- • Higher leverage amplifies both gains and losses
- • Never invest more than you can afford to lose
Tags
Similar Stocks Assets
Explore other stocks instruments in the same sector as Avidity Biosciences, Inc.. Compare performance and find trading opportunities.

AeroVironment, Inc.
ProShares UltraShort Silver

Tempus AI, Inc

Ondas Holdings Inc.

FTAI Aviation Ltd.
Frequently Asked Questions
Avidity Biosciences, Inc. is a stocks instrument available for trading on CoinUnited.io.
Disclaimers & References
Important Risk Disclaimer
A CoinUnited stock CFD gives price exposure to Avidity Biosciences, Inc. only, not equity ownership: no shareholder voting rights, no dividends, and no settlement in the underlying share.
Leverage magnifies losses as well as gains, and a position can be liquidated long before the underlying share price recovers. The underlying listing trades on exchange hours, so the reference price can gap between sessions.
Users should conduct their own research and consult with qualified financial professionals before making any investment decisions. The creators and operators of this platform assume no responsibility for any financial losses or other damages that may result from reliance on the information provided.
Leveraged trading is extremely risky and you may lose your entire deposit.
Methodology Overview
Figures on this page are compiled from primary and named third-party sources, not produced by a forecasting model. Each one carries its source and date in the Source Map above.
- Financial statements: the company's own SEC filings (10-K / 10-Q), read from XBRL
- Market data: the CoinUnited reference price and daily closes
- Institutional ownership: SEC Form 13F quarterly filings
- Analyst targets: aggregated third-party sell-side coverage — third-party opinion, not CoinUnited's view
- Peer multiples: third-party trailing-twelve-month ratios
CoinUnited does not publish a price forecast or target for Avidity Biosciences, Inc..
Last methodology review:
Ready to Start Trading Avidity Biosciences, Inc.?
Join thousands of traders and start your Avidity Biosciences, Inc. trading journey today. Get access to advanced trading tools and competitive fees.



